These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33539817)

  • 1. Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1.
    Wu Q; Chen DQ; Sun L; Huan XJ; Bao XB; Tian CQ; Hu J; Lv KK; Wang YQ; Xiong B; Miao ZH
    Biochem Pharmacol; 2021 Mar; 185():114435. PubMed ID: 33539817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
    Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
    J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains.
    Bouché L; Christ CD; Siegel S; Fernández-Montalván AE; Holton SJ; Fedorov O; Ter Laak A; Sugawara T; Stöckigt D; Tallant C; Bennett J; Monteiro O; Díaz-Sáez L; Siejka P; Meier J; Pütter V; Weiske J; Müller S; Huber KVM; Hartung IV; Haendler B
    J Med Chem; 2017 May; 60(9):4002-4022. PubMed ID: 28402630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pseudo-Natural Product Tafbromin Selectively Targets the TAF1 Bromodomain 2.
    Patil S; Cremosnik G; Dötsch L; Flegel J; Schulte B; Maier KC; Žumer K; Cramer P; Janning P; Sievers S; Ziegler S; Waldmann H
    Angew Chem Int Ed Engl; 2024 Aug; 63(32):e202404645. PubMed ID: 38801173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
    Damaneh MS; Hu JP; Huan XJ; Song SS; Tian CQ; Chen DQ; Meng T; Chen YL; Shen JK; Xiong B; Miao ZH; Wang YQ
    Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain.
    Karim RM; Yang L; Chen L; Bikowitz MJ; Lu J; Grassie D; Shultz ZP; Lopchuk JM; Chen J; Schönbrunn E
    J Med Chem; 2022 Mar; 65(5):4182-4200. PubMed ID: 35191694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
    Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
    Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
    Gold S; Shilatifard A
    Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer.
    Li J; Zhu R; Zhuang X; Zhang C; Shen H; Wu X; Zhang M; Huang C; Xiang Q; Zhao L; Xu Y; Zhang Y
    Bioorg Chem; 2023 Jun; 135():106495. PubMed ID: 37004437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
    Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun SY
    Cancer Lett; 2018 Oct; 435():44-54. PubMed ID: 30059709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
    Hu J; Tian CQ; Damaneh MS; Li Y; Cao D; Lv K; Yu T; Meng T; Chen D; Wang X; Chen L; Li J; Song SS; Huan XJ; Qin L; Shen J; Wang YQ; Miao ZH; Xiong B
    J Med Chem; 2019 Sep; 62(18):8642-8663. PubMed ID: 31490070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zinc knuckle of TAF1 is a DNA binding module critical for TFIID promoter occupancy.
    Curran EC; Wang H; Hinds TR; Zheng N; Wang EH
    Sci Rep; 2018 Mar; 8(1):4630. PubMed ID: 29545534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism.
    Hernández IH; Cabrera JR; Santos-Galindo M; Sánchez-Martín M; Domínguez V; García-Escudero R; Pérez-Álvarez MJ; Pintado B; Lucas JJ
    Brain; 2020 Jul; 143(7):2207-2219. PubMed ID: 32533168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1.
    Suh JL; Watts B; Stuckey JI; Norris-Drouin JL; Cholensky SH; Dickson BM; An Y; Mathea S; Salah E; Knapp S; Khan A; Adams AT; Strahl BD; Sagum CA; Bedford MT; James LI; Kireev DB; Frye SV
    Biochemistry; 2018 Apr; 57(14):2140-2149. PubMed ID: 29558110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.